vTv Therapeutics (VTVT) Q4 2024 earnings summary

Executive summary

• Clinical hold on cadisegliatin program lifted by FDA in March 2025, allowing Phase 3 CATT1 trial in type 1 diabetes to resume in Q2 2025 after protocol amendment shortens trial duration from 12 to 6 months.

• Appointment of Martin Lafontaine as Chief Commercial Officer to strengthen commercial leadership for late-stage diabetes program.

Financial highlights

• Cash position at December 31, 2024, was $36.7 million, up from $9.4 million a year earlier, mainly due to private placement financing and ATM offering.

• Net loss for Q4 2024 was $3.6 million ($0.55 per share) compared to $3.5 million ($1.67 per share) in Q4 2023.

• Full year 2024 net loss was $18.5 million ($3.20 per share), improved from $20.3 million ($9.71 per share) in 2023.

• R&D expenses for 2024 were $11.5 million, down from $13.6 million in 2023, mainly due to lower spending on cadisegliatin and other projects.

• G&A expenses for 2024 were $13.7 million, up from $11.9 million in 2023, driven by higher payroll and share-based expenses.

• Interest income for 2024 was $1.6 million, up from $0.5 million in 2023, due to money market account returns.

Outlook and guidance

• Phase 3 CATT1 trial for cadisegliatin in T1D expected to resume in Q2 2025, with protocol amendment accelerating topline data and pivotal study initiation.